Morgan Stanley's Seven-Factor Framework: Where Are the Structural Opportunities in Chinese Equities?
N.R. Finch
Morgan Stanley built a seven-factor model to stress-test China allocation. Its core call: valuation, currency, and marginal earnings improvement already provide support — but active capital and policy catalysts are still missing, and whether they converge in H2 will determine if the rally lasts.
What does the seven-factor framework actually say?
The seven factors are: earnings growth, valuation, liquidity, policy cycle, currency, geopolitics, and sector regulation.
This means → Morgan Stanley no longer judges China on a single metric. It requires at least three factors moving meaningfully in the same direction to trigger a rating change.
In plain terms = one or two small improvements justify a target-price tweak at most. A real re-allocation needs multiple variables moving together.
Are earnings improving? By how much?
The share of A-share earnings misses narrowed from roughly −23% in Q4 2025 to roughly −13% in Q1 2026.
This means → the direction is better, but Morgan Stanley frames it as "going from very bad to not quite as bad" — not a broad recovery.
Improvement is concentrated in energy and upstream materials. Consumer and downstream sectors remain weak — the transmission chain has not connected.
Valuations are cheap — so why hasn't the market moved?
MSCI China's 12-month forward P/E sits at roughly 10.9×, below its five-year average of 11.8×, at a ~10% discount to emerging markets — the lowest tier globally.
In plain terms = Chinese equities are genuinely cheap, but Morgan Stanley states clearly: cheap alone is not a catalyst.
Earnings, fund flows, currency, and policy each need to cooperate before "cheap" translates into a sustainable rally.
Is foreign capital actually buying — or leaving?
Net foreign inflows in the first five months of 2026 already reached ~80% of the 2025 full-year total, but the bulk came from passive ETFs, not active funds.
Global active long-only funds remain deeply underweight China: global funds by ~1.3 pp, EM funds by ~5.7 pp — wider than the 3–4 pp underweight at the start of the year.
This means → ETF buying shows global capital is not bearish on EM as a whole, but active money is waiting for clearer earnings and thematic signals. Korea and Taiwan, riding the AI-hardware and semiconductor cycle, keep outperforming — they are the main opportunity cost of reallocating back to China.
Currency and geopolitics — which helps, which drags?
USD/CNY has pulled back from 7.3–7.4 in early 2025 to roughly 6.8, with a year-end forecast of about 6.75 — a marginal tailwind for Chinese equities.
Near-term U.S.–China talks may yield symbolic progress and tariff extensions, but the long-term framework remains competitive confrontation.
This reflects a structural shift: U.S. investors' holdings in MSCI China constituents have fallen from ~17% in 2018 to ~10% today.
What does Morgan Stanley recommend buying — and why lean toward A-shares?
Overweight sectors: energy/materials, advanced manufacturing, semiconductors, and insurance. Medium-to-long-term themes: AI, energy security, social change, and tech innovation.
Compared with Hong Kong-listed stocks, Morgan Stanley leans toward A-shares — arguing that A-shares align better with those themes in structure, index weight, and exposure.
Macro backdrop: 2026 real GDP growth forecast is ~4.8%, led mainly by exports; PPI turned positive in April but driven by upstream price gains. This means → with exports strong and Q1 GDP running high, Morgan Stanley judges that the urgency for large-scale fiscal stimulus in H2 has actually decreased.
Content is for reference only, not financial advice.